271 related articles for article (PubMed ID: 19770660)
1. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
Harper L
Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
[TBL] [Abstract][Full Text] [Related]
3. [Cyclophosphamide in ANCA associated vasculitis: continuous oral vs pulse therapy].
Serpieri N
G Ital Nefrol; 2010; 27(6):566. PubMed ID: 21132637
[No Abstract] [Full Text] [Related]
4. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
Rich EN; Brown KK
Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
[TBL] [Abstract][Full Text] [Related]
5. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
Rutgers A; Kallenberg CG
Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
[TBL] [Abstract][Full Text] [Related]
6. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
7. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
Holle JU; Gross WL
J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR;
Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882
[TBL] [Abstract][Full Text] [Related]
9. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
Kötter I
Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
[No Abstract] [Full Text] [Related]
10. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA; Flores-Suárez LF
Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
[TBL] [Abstract][Full Text] [Related]
13. Changing landscape of immunosuppression in ANCA-associated vasculitis.
Moiseev SV; Smitienko I; Bulanov N; Karovaikina E; Novikov PI
Ann Rheum Dis; 2020 May; 79(5):e59. PubMed ID: 30755415
[No Abstract] [Full Text] [Related]
14. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
15. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
16. Systemic vasculitis: still a challenging disease.
Buhaescu I; Covic A; Levy J
Am J Kidney Dis; 2005 Aug; 46(2):173-85. PubMed ID: 16112036
[TBL] [Abstract][Full Text] [Related]
17. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience.
Rihová Z; Jancová E; Merta M; Zabka J; Rysavá R; Bartůnková J; Kolárova I; Tesar V
Prague Med Rep; 2004; 105(1):64-8. PubMed ID: 15354947
[TBL] [Abstract][Full Text] [Related]
18. The future of ANCA-associated vasculitis.
Holle JU; Wieczorek S; Gross WL
Rheum Dis Clin North Am; 2010 Aug; 36(3):609-21. PubMed ID: 20688253
[TBL] [Abstract][Full Text] [Related]
19. Review article: Progress of treatment in ANCA-associated vasculitis.
Jayne D
Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
